PUBLISHER: The Insight Partners | PRODUCT CODE: 1715184
PUBLISHER: The Insight Partners | PRODUCT CODE: 1715184
The South & Central America blood collection tubes for liquid biopsy market was valued at US$ 3,304.16 million in 2023 and is expected to reach US$ 12,431.43 million by 2031; it is estimated to register a CAGR of 18.0% from 2023 to 2031.
Use of Liquid Biopsy in Cancer Monitoring Fuels South & Central America Blood Collection Tubes for Liquid Biopsy Market
There is a growing focus on employing liquid biopsy procedures for monitoring cancer growth, detecting genetic mutations, identifying signs of relapse, and predicting sensitivity to immunotherapy. The early detection of cancer results in better outcomes; for example, patients with early detection show higher remission and survival rates than those with late-stage or malignant cancer. However, it is impractical to perform serial radiological testing or invasive procedures for cancer surveillance to detect cancer in the early stages when symptoms are not evident. Liquid biopsy unlocks the possibility of periodic cancer screening through routine blood draws or urinalyses. It can identify highly specific and circulating markers for early cancer detection.
Liquid biopsy procedures are also employed for post-treatment monitoring of cancer patients. Cancer cells may persist in the body after treatment at levels below the resolution and detection levels of imaging studies; the condition is termed a minimal residual disease. This disease is considered a principal cause of cancer remission. Similar to that in cancer screening and early detection, the clinical application of liquid biopsy is limited by the sensitivity and specificity of current tests. However, due to this sensitivity limitation, liquid biopsy techniques can be used for detecting minimal residual disease for solid tumors than blood cancers. With the help of liquid biopsy, the healthcare professional can monitor the case of reoccurrence of cancer, which can then be treated early with the help of proper diagnosis.
Tumors that are initially susceptible to specific tyrosine kinase inhibitors, including gefitinib, erlotinib, crizotinib, and ceritinib, often mutate and develop resistance to these drugs. Liquid biopsy detects the changes in the tumor status and helps doctors modify the treatment strategies to avoid the development of resistance to any medication in the patient's body. Thus, liquid biopsy allows the early detection of cancer and helps healthcare professionals determine the exact course of action for treatment. In addition, it helps monitor treatments and the condition of the patient after the treatment. Thus, there is an increase in focus on the use of liquid biopsy in the monitoring of cancer patients, which is likely to create a significant demand for blood collection tubes for liquid biopsy procedures during the forecast period.
South & Central America Blood Collection Tubes for Liquid Biopsy Market Overview
The blood collection tube for liquid biopsy market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. The market growth in the region is attributed to factors such as the high prevalence of chronic disease, and the burgeoning demand for laboratory testing. Tubes play a vital role in healthcare settings in Brazil as the dependence on precise and effective diagnostics is increasing with advancements in facilities. The collection, transfer, and examination of blood samples is an integral part of medical tests such as disease screening and blood chemistry analysis as well as in blood transfusion. In 2021, the country reported an increase of 7.3% in the imports of medical devices, reaching the value of US$ 6.2 billion. As per estimates by the Brazilian Ministry of Health, ~3 million units of blood are collected each year in Brazil; out of the total blood collected, ~70% of donations in these regions are collected through the public system. Thus, an increase in demand for blood collection tubes will likely drive the market growth.
South & Central America Blood Collection Tubes for Liquid Biopsy Market Revenue and Forecast to 2031 (US$ Million)
South & Central America Blood Collection Tubes for Liquid Biopsy Market Segmentation
The South & Central America blood collection tubes for liquid biopsy market is categorized into product, material, application, end user, country.
By product, the South & Central America blood collection tubes for liquid biopsy market is segmented into ccfDNA/cfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, intracellular RNA Tubes, and others. The ccfDNA/cfDNA Tubes segment held the largest share of the South & Central America blood collection tubes for liquid biopsy market share in 2023.
In terms of material, the South & Central America blood collection tubes for liquid biopsy market is segmented into plastic and glass. The plastic segment held a larger share of the South & Central America blood collection tubes for liquid biopsy market share in 2023.
By application, the South & Central America blood collection tubes for liquid biopsy market is bifurcated into in-vitro diagnostics (IVD) and research. The in-vitro diagnostics (IVD) segment held a larger share of the South & Central America blood collection tubes for liquid biopsy market share in 2023.
In terms of end user, the South & Central America blood collection tubes for liquid biopsy market is segmented into genetic diagnostic labs, research and development centers, conventional diagnostic centers, and others. The genetic diagnostic labs segment held the largest share of the South & Central America blood collection tubes for liquid biopsy market share in 2023.
Based on country, the South & Central America blood collection tubes for liquid biopsy market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil segment held the largest share of South & Central America blood collection tubes for liquid biopsy market in 2023.
Biocept Inc; Exact Sciences Corp; F. Hoffmann-La Roche Ltd; Greiner Bio-One International GmbH; MagBio Genomics, Inc; Norgen Biotek Corp; QIAGEN NV; Streck Inc; and Zymo Research Corporation are some of the leading companies operating in the South & Central America blood collection tubes for liquid biopsy market.